Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Takeda Pharmaceutical Ltd ADR (NY: TAK )

13.40 +0.07 (+0.56%)
Streaming Delayed Price Updated: 2:31 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Takeda Pharmaceutical Ltd ADR

< Previous 1 2
...
11 12 13 14 15 16 17 18 Next >
Attention Biotech Investors: Mark Your Calendar For November PDUFA Dates
The loaded Prescription Drug User Fee Act (PDUFA) calendar for October produced mixed outcomes. PDUFA dates are key binary events for biotech stocks that can move the needle in a... 
Via Benzinga
Takeda Applied for Selection of “Prime Market”, Filed Corporate Governance Report With Tokyo Stock Exchange (TSE) in Line With Revised Corporate Governance Code and Published Corporate Governance Related Documents on its Website
From Takeda Pharmaceutical Company Limited
Via Business Wire
No Negative Reaction
Today the impact of the Delta variant hit US GDP which was only 2% annualized, vs estimates of 2.6%, based on Q3 data which came out today. 
Via Talk Markets
Earnings Scheduled For October 28, 2021
Companies Reporting Before The Bell • LendingTree (NASDAQ:TREE) is estimated to report quarterly earnings at $0.57 per share on revenue of $292.63 million. •... 
Via Benzinga
Takeda's 1H Sales Increase 13%, Reaffirms FY21 Outlook, Announces Share Buyback
Takeda Pharmaceutical Company Limited (NYSE: TAK) reported 1H FY21 sales of ¥1,794.4 billion, +12.8%. Underlying core revenue increased +6.8% Y/Y, driven by 14... 
Via Benzinga
Takeda Announces Acquisition of Own Shares
From Takeda Pharmaceutical Company Limited
Via Business Wire
Takeda Delivers Strong H1 FY2021 Results; Further Growth Momentum Expected Through Fiscal Year-End Driven by 14 Global Brands
From Takeda Pharmaceutical Company Limited
Via Business Wire
Takeda to Acquire GammaDelta Therapeutics to Accelerate Development of Allogeneic γδT Cell Therapies Addressing Solid Tumors
From Takeda Pharmaceutical Company Limited
Via Business Wire
Wednesday Market Coverage
Today gold rose again despite the active market for bitcoin and the lower Chinese demand for mine products like iron and coal. 
Via Talk Markets
Leading the Charge to Develop the First Orexin-Targeted Therapy to Address Narcolepsy at its Root Cause
Photo by MART PRODUCTION from Pexels The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial... 
Via Benzinga
Bitcoin Futures Arrive
Today you can finally hold Bitcoins via an exchange-traded fund. 
Via Talk Markets
The Daily Biotech Pulse: Entasis, Dermata Spike Higher On Positive Readouts, J&J Q3 EPS Beats Estimates, Wave Life Sciences Regains Right To CNS Portfolio
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Entasis Announces Positive Data For Late-Stage Study Of SUL-DUR In... 
Via Benzinga
Wave Life Sciences, Takeda Discontinue Research On Preclinical CNS Programs
Wave Life Sciences Ltd (NASDAQ: WVE) has amended its ongoing collaboration with Takeda Pharmaceutical Company Limited (NYSE: TAK) to discontinue... 
Via Benzinga
Calithera Buys Two Oncology Candidates From Takeda For $45M
Calithera Biosciences Inc (NASDAQ: CALA) has agreed to acquire two clinical-stage cancer-focused compounds from Takeda Pharmaceutical Company Limited (NYSE: TAK).... 
Via Benzinga
Chinese Growth Level
The hot news today was a much weaker Chinese growth level this year, of 4.9% because of supply chain issues. 
Via Talk Markets
Europe's Unicorns
After markets jumped yesterday, we saw a lot of bounce today although gold fell back a bit. 
Via Talk Markets
Health Care Sector Appears to Be a Drag on Positive UnitedHealth Earnings
Stock futures were pointing to a higher open even before Goldman Sachs (NYSE: GS) reported better than expected earnings. Goldman rose 2.25% before the open helping to... 
Via Benzinga
BioLife Plasma Services Announces Expansion of Plasma Donation Centers into Massachusetts
From Takeda Pharmaceutical Company Limited
Via Business Wire
The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 7) Alkermes plc (NASDAQ: ALKS)... 
Via Benzinga
Exposures Product Safety
FDA Advisory Committee Recommends Use of Investigational Drug Maribavir (TAK-620) to Treat Post-Transplant Recipients with Cytomegalovirus (CMV) Infection and Disease Refractory to Treatment With or Without Resistance
From Takeda Pharmaceutical Company Limited
Via Business Wire
Perfumes Of Arabia
Downtrends do eventually run out of pessimistic steam, but it can take a while. 
Via Talk Markets
Why Takeda Pharmaceutical Stock Is Down More Than 10% Today
The prescription drugmaker is halting a trial before a scheduled stopping point, suggesting it's too dangerous to expect an approval. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For October 7, 2021
Upgrades For State Street Corporation (NYSE: 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Voyager Therapeutics (NASDAQ:VYGR) shares moved upwards by 44.73% to $3.58 during Wednesday's regular session. Voyager Therapeutics's stock is trading at a... 
Via Benzinga
BofA Downgrades Takeda On Suspension Narcolepsy Drug Trials
Takeda Pharmaceutical Co Ltd (NYSE:TAK) announced the... 
Via Benzinga
Takeda Stock Nears Two-Year Low After This Issue Shuttered Two Narcolepsy Tests
Takeda Pharmaceutical was testing a drug called TAK-994 in narcolepsy patients. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Voyager Therapeutics (NASDAQ:VYGR) shares increased by 46.15% to $3.61 during Wednesday's pre-market session. The company's market cap stands at $136.9... 
Via Benzinga
Takeda Discontinues Two Mid-Stage Narcolepsy Trials
Takeda Pharmaceutical Company Limited (NYSE: TAK) has suspended dosing and has decided to stop Phase 2 studies evaluating TAK-994, an investigational oral orexin... 
Via Benzinga
Takeda Provides Update on TAK-994 Clinical Program
From Takeda Pharmaceutical Company Limited
Via Business Wire
The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 5) Bicycle Therapeutics plc (... 
Via Benzinga
< Previous 1 2
...
11 12 13 14 15 16 17 18 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.